tetano
Editor, Senior Moderator
J Cardiovasc Dev Dis
. 2021 Nov 29;8(12):167.
doi: 10.3390/jcdd8120167.
A Population-Based Registry Analysis on Hospitalized COVID-19 Patients with Previous Cardiovascular Disease: Clinical Profile, Treatment, and Predictors of Death
Eduardo Gutiérrez-Abejón[SUP] 1 2 3 [/SUP], Francisco Herrera-Gómez[SUP] 1 3 4 5 6 [/SUP], Débora Martín-García[SUP] 7 [/SUP], Eduardo Tamayo[SUP] 6 8 9 [/SUP], Francisco Javier Álvarez[SUP] 1 3 6 10 [/SUP]
Affiliations
Abstract
A high percentage of patients with COVID-19 (coronavirus disease 2019) have previous cardiovascular disease (CVD). The findings presented here came from an epidemiological population-based registry study (real-world data) that enrolled all in-hospital COVID-19 patients with previous CVD from 1 March to 31 May 2020. Death, other comorbidities, hospital stay variables, ventilation type, and main clinical outcomes were evaluated. In Castile and Leon, 35.83% of the 7307 in-hospital COVID-19 patients who participated in this study had previous CVD, particularly arrhythmias (48.97%), cerebrovascular disease (25.02%), ischemic heart disease (22.8%), and chronic heart failure (20.82%). Of the patients, 21.36% were men and more than 90% were over 65 years of age, and the mortality rate achieved 32.93%. The most used medicines were antibiotics (91.41%), antimalarials (73.3%), steroids (46.64%), and antivirals (43.16%). The main predictors of death were age over 65 years (OR: 5), ventilation needs (OR: 2.81), treatment with anti-SIRS (systemic inflammatory response syndrome) medicines (OR: 1.97), antivirals (OR: 1.74) or steroids (OR: 1.68), SIRS (OR: 5.75), SARS (severe acute respiratory syndrome) (OR: 2.44), or AKI (acute kidney injury) (OR: 1.63) occurrence. Chronic heart failure and cerebrovascular disease were associated with a worse clinical course of COVID-19, especially in men older than 65 years with diabetes who developed SIRS, SARS, or AKI.
Keywords: COVID-19; SARS-CoV-2; cardiovascular diseases; cerebrovascular diseases; clinical characteristics; heart failure; mortality; treatment.
. 2021 Nov 29;8(12):167.
doi: 10.3390/jcdd8120167.
A Population-Based Registry Analysis on Hospitalized COVID-19 Patients with Previous Cardiovascular Disease: Clinical Profile, Treatment, and Predictors of Death
Eduardo Gutiérrez-Abejón[SUP] 1 2 3 [/SUP], Francisco Herrera-Gómez[SUP] 1 3 4 5 6 [/SUP], Débora Martín-García[SUP] 7 [/SUP], Eduardo Tamayo[SUP] 6 8 9 [/SUP], Francisco Javier Álvarez[SUP] 1 3 6 10 [/SUP]
Affiliations
- PMID: 34940522
- DOI: 10.3390/jcdd8120167
Abstract
A high percentage of patients with COVID-19 (coronavirus disease 2019) have previous cardiovascular disease (CVD). The findings presented here came from an epidemiological population-based registry study (real-world data) that enrolled all in-hospital COVID-19 patients with previous CVD from 1 March to 31 May 2020. Death, other comorbidities, hospital stay variables, ventilation type, and main clinical outcomes were evaluated. In Castile and Leon, 35.83% of the 7307 in-hospital COVID-19 patients who participated in this study had previous CVD, particularly arrhythmias (48.97%), cerebrovascular disease (25.02%), ischemic heart disease (22.8%), and chronic heart failure (20.82%). Of the patients, 21.36% were men and more than 90% were over 65 years of age, and the mortality rate achieved 32.93%. The most used medicines were antibiotics (91.41%), antimalarials (73.3%), steroids (46.64%), and antivirals (43.16%). The main predictors of death were age over 65 years (OR: 5), ventilation needs (OR: 2.81), treatment with anti-SIRS (systemic inflammatory response syndrome) medicines (OR: 1.97), antivirals (OR: 1.74) or steroids (OR: 1.68), SIRS (OR: 5.75), SARS (severe acute respiratory syndrome) (OR: 2.44), or AKI (acute kidney injury) (OR: 1.63) occurrence. Chronic heart failure and cerebrovascular disease were associated with a worse clinical course of COVID-19, especially in men older than 65 years with diabetes who developed SIRS, SARS, or AKI.
Keywords: COVID-19; SARS-CoV-2; cardiovascular diseases; cerebrovascular diseases; clinical characteristics; heart failure; mortality; treatment.